CHICAGO, June 26 -- In the month since the New England Journal of Medicine published a meta-analysis that linked use of rosiglitazone (Avandia) to an increased risk of myocardial infarction, controversy surrounding the use of this popular diabetes drug has continued unabated. Earlier this month a Congressional hearing investigated the FDA's handling of rosiglitazone and several medical journals have weighed in with editorials on the controversy. The American Diabetes Association addressed the issue at a special symposium.
SEE LINK BELOW :
http://www.medpagetoday.com/MeetingCoverage/ADAMeeting/tb1/6022
No comments:
Post a Comment